AstraZeneca Strikes $1.5B AI Drug Discovery Deal

AstraZeneca is expanding its use of artificial intelligence in pharmaceutical research through a new partnership with biotechnology company insitro, committing $40 million upfront to discover potential treatments for difficult-to-treat liver and heart conditions. The collaboration could generate up to approximately $1.46 billion in additional milestone payments for insitro, alongside royalties on future sales, as the companies seek to use AI to identify the biological mechanisms driving disease.